Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor
receptor (EGFR) gene were among the first EGFR mutations to be identified as oncogenic …

Human malignancies are often the result of overexpressed and constitutively active receptor
and non-receptor tyrosine kinases, which ultimately lead to the mediation of key tumor …

Objectives The tyrosine kinase inhibitor (TKI)-sensitive mutations of the epidermal growth
factor receptor (EGFR) gene is essential in the treatment of lung adenocarcinoma. To …

Background Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of
progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth …

Lung cancer is the leading cause of cancer death worldwide. Molecular targeted therapy
has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which …

Identification of epidermal growth factor receptor (EGFR) as a molecular target has radically
changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard …

Precision medicine has become a novel and rising concept, which depends much on the
identification of individual genomic signatures for different patients. The cancer cell lines …

Targeted therapies have changed the landscape of treatments for non-small cell lung cancer
(NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring …

Non-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung
cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic …

The epidermal growth factor receptor (EGFR) is historically the prototypical receptor tyrosine
kinase, being the first cloned and the first where the importance of ligand-induced dimer …